Shots:
- Takeda has terminated its collaboration with Denali for the co-development & commercialization of DNL593, citing strategic considerations unrelated to safety or efficacy
- Denali will regain full control of DNL593, a progranulin replacement therapy leveraging its Protein TransportVehicle platform to cross the blood-brain barrier for the treatment of frontotemporal dementia
- The ongoing P-I/II study has completed enrollment (n=40), with interim data showing dose-dependent increases in CSF progranulin & no significant safety signals to date; results are expected by the end of 2026
Ref: Globenewswire | Image: Denali & Takeda |Press Release
Related News: Axsome Therapeutics Acquires Global Rights to Balipodect from Takeda
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
